---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-276209"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:12:56.291776+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Atara Q3 net loss $4.3M; cash $13.7M; tab-cel BLA PDUFA Jan 10, 2026

## Summary
- Cash and equivalents $13.7M as of Sep 30, 2025, down from $22.3M at Jun 30.
- Net loss of $4.3M ($0.32 per share) vs. $21.9M loss a year ago.
- Total revenues $3.5M, down from $40.2M in Q3 2024 due to deferred revenue recognition.
- Workforce reduced ~29% in Oct 2025; ~15 employees now retained.
- FDA accepted tab-cel BLA with Priority Review; $40M milestone due from Pierre Fabre upon approval.

## SEC filing metadata
- accession: 0001193125-25-276209
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000119312525276209/0001193125-25-276209-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000119312525276209/d66575d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-276209
- JSON: https://secwatch.observer/filing/0001193125-25-276209.json
- Plain text: https://secwatch.observer/filing/0001193125-25-276209.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.